Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Cecilie Laurberg Christoffersen"'
Autor:
Piero Barbanti, Peter J. Goadsby, Giorgio Lambru, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background The multinational phase 3b DELIVER trial was designed to evaluate the efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures across 17 countries. In the placebo-controlled p
Externí odkaz:
https://doaj.org/article/7a81ae83aa2c4873bde25a68ab3a5515
Autor:
Peter J. Goadsby, Piero Barbanti, Giorgio Lambru, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling
Publikováno v:
European journal of neurology.
In the phase 3b, randomized, double-blind, placebo-controlled DELIVER clinical trial, eptinezumab reduced migraine frequency and headache in adults with two to four prior preventive treatment failures. Here the effect of eptinezumab on coinciding pat
Autor:
Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling, Patricia Pozo-Rosich
Publikováno v:
Scientia
Chronic migraine; Episodic migraine; Eptinezumab Migraña crónica; Migraña episódica; Eptinezumab Migranya crònica; Migranya episòdica; Eptinezumab Background Migraine is a disabling neurological disease adversely affecting many aspects of life.
Autor:
Peter Goadsby, Piero Barbanti, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Bjørn Sperling, Caroline Defawe Rajca
Publikováno v:
Revue Neurologique. 179:S41
Autor:
Messoud Ashina, Michel Lanteri-Minet, Patricia Pozo-Rosich, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling
Publikováno v:
The Lancet. Neurology. 21(7)
The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and acceptable safety and tolerability in phase 3 trials, but benefits in the subpopulations
Autor:
Ashina, Messoud1 (AUTHOR) ashina@dadlnet.dk, Lanteri-Minet, Michel2,3 (AUTHOR), Ettrup, Anders4 (AUTHOR), Christoffersen, Cecilie Laurberg4 (AUTHOR), Josiassen, Mette Krog4 (AUTHOR), Phul, Ravinder4 (AUTHOR), Sperling, Bjørn4 (AUTHOR), Pozo-Rosich, Patricia5,6 (AUTHOR)
Publikováno v:
Cephalalgia. May2023, Vol. 43 Issue 5, p1-11. 11p.
Autor:
Ashina, Messoud, Tepper, Stewart J., Gendolla, Astrid, Sperling, Bjørn, Ettrup, Anders, Josiassen, Mette Krog, Starling, Amaal J.
Publikováno v:
Journal of Headache & Pain; 11/20/2023, Vol. 24 Issue 1, p1-13, 13p
Autor:
Goadsby, Peter J., Barbanti, Piero, Lambru, Giorgio, Ettrup, Anders, Christoffersen, Cecilie Laurberg, Josiassen, Mette Krog, Phul, Ravinder, Sperling, Bjørn
Publikováno v:
European Journal of Neurology; Apr2023, Vol. 30 Issue 4, p1089-1098, 10p
Autor:
Barbanti, Piero, Goadsby, Peter J., Lambru, Giorgio, Ettrup, Anders, Christoffersen, Cecilie Laurberg, Josiassen, Mette Krog, Phul, Ravinder, Sperling, Bjørn
Publikováno v:
Journal of Headache & Pain; 12/2/2022, Vol. 23 Issue 1, p1-10, 10p
Publikováno v:
Clinical Trials Week; 12/18/2023, p1110-1110, 1p